Antibody–drug conjugates in combination therapy: defining the next chapter☆

Antibody–drug conjugates (ADCs) have become an established therapeutic class, with 14 agents approved to date by the United States Food and Drug Administration across diverse malignancies (Table 1). By selectively delivering highly potent cytotoxins to cells expressing tumor-associated targets, ADCs can induce meaningful tumor regression even among patients who are heavily pretreated or have refractory disease. However, the durability of…